Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMBR | P28336 | 2/20 | 0.68 |
| ▸ | GRPR | P30550 | 2/20 | 0.68 |
| ▸ | C5AR1 | P21730 | 2/20 | 0.66 |
| ▸ | GLP1R | P43220 | 5/20 | 0.65 |
| ▸ | GCGR | P47871 | 5/20 | 0.65 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.61 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.61 |
| ▸ | F2 | P00734 | 4/20 | 0.60 |
| ▸ | CALCR | P30988 | 3/20 | 0.60 |
| ▸ | APLNR | P35414 | 1/20 | 0.59 |
| ▸ | GIPR | P48546 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29413122 | 0.88 | APLNR (0.69) | C5AR1CRHR1CRHR2F2CALCR | |
| SCHEMBL30595937 | 0.87 | GLP1R (0.74) | NMBRGRPRGLP1RGCGRCRHR1 | |
| SCHEMBL30358196 | 0.87 | CALCR (0.69) | NMBRGRPRGLP1RGCGRCALCR | |
| SCHEMBL29363376 | 0.87 | APLNR (0.68) | C5AR1CRHR1CRHR2F2CALCR | |
| Exenatide SCHEMBL29352797 | 0.87 | GLP1R (0.75) | GLP1RGCGRCRHR1CRHR2CALCR | |
| Cosyntropin SCHEMBL30506076 | 0.86 | C5AR1 (0.72) | NMBRGRPRC5AR1GLP1RGCGR | |
| SCHEMBL31182680 | 0.86 | GLP1R (0.74) | NMBRGRPRC5AR1GLP1RGCGR | |
| SCHEMBL30906343 | 0.86 | GLP1R (0.65) | NMBRGRPRC5AR1GLP1RGCGR | |
| SCHEMBL30262076 | 0.85 | C5AR1 (0.62) | NMBRGRPRC5AR1GLP1RGCGR | |
| SCHEMBL31182484 | 0.85 | KEAP1 (0.72) | GLP1RGCGRCALCRGIPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111032689-B | Anti-apelin peptide antibody and application thereof | 凡恩世制药(北京)有限公司 | 2024-02-27 | — | — | CN | claimed |
| US-20230145276-A1 | AEROSOLIZED FORMULATIONS OF AN APELIN PEPTIDE AND USES THEREOF | CHAN JOHN (US) | 2023-05-11 | — | — | US | claimed |
| US-11642390-B2 | Method of treatment with a fusion protein comprising apelin and an anti-APLNR antibody | Regeneran Pharmaceuticals, Inc. (US) | 2023-05-09 | — | — | US | claimed |
| CN-108703971-B | Application of anti-HIV (human immunodeficiency virus) medicament, namely, cobicistat, in preparation of antithrombotic medicament | 南华大学 | 2023-04-07 | — | — | CN | claimed |
| US-11400049-B2 | Pegylated liposomal formulations of apelin for treatment of cardiovascular-related diseases | AVIVE, INC. (US) | 2022-08-02 | — | — | US | claimed |
| US-11365242-B2 | Anti-apelin antibodies and uses thereof | PHANES THERAPEUTICS, INC. (US) | 2022-06-21 | — | — | US | claimed |
| US-20220096380-A1 | ORAL FORMULATIONS OF A BIOLOGICALLY ACTIVE PEPTIDE AND USES THEREOF | AVIVE INC (US) | 2022-03-31 | — | — | US | claimed |
| CN-114040771-A | Oral formulations of bioactive peptides and uses thereof | 阿维夫公司 | 2022-02-11 | — | — | CN | claimed |
| US-20260097051-A1 | CANNABICHROMENE AS A THERAPEUTIC MODALITY FOR COVID-19 | AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC. (US) | 2026-04-09 | — | — | US | disclosed |
| EP-4720107-A1 | A FUSION PEPTIDE FOR ACTIVATION OF THE APJ AND / OR GLP-1 RECEPTORS | University Of Ulster (GB) | 2026-04-08 | — | — | EP | disclosed |
| EP-4225772-B1 | CYCLIC APELIN RECEPTOR AGONISTS | NXERA PHARMA UK LTD (GB) | 2026-02-25 | — | — | EP | disclosed |
| US-20260049331-A1 | Sense-and-Response of Proteins, Peptides, and Small Molecules Using Ligand-Induced Dimerization Activating RNA Editing (LIDAR) | UNIV LELAND STANFORD JUNIOR (US) | 2026-02-19 | — | — | US | disclosed |
| EP-4695270-A1 | APELIN RECEPTOR AGONISTS AND USES THEREOF | Otsuka Pharmaceutical Co., Ltd. (JP) | 2026-02-18 | — | — | EP | disclosed |
| US-20260041732-A1 | USE OF APELIN FOR THE TREATMENT OF LYMPHEDEMA | INST NAT SANTE RECH MED (FR) | 2026-02-12 | — | — | US | disclosed |
| CN-108368087-B | 2, 4-dihydroxy-nicotinamide as APJ agonists | 百时美施贵宝公司 | 2022-04-12 | — | — | CN | disclosed |
| US-20220096380-A1 | ORAL FORMULATIONS OF A BIOLOGICALLY ACTIVE PEPTIDE AND USES THEREOF | AVIVE INC (US) | 2022-03-31 | — | — | US | disclosed |
| CN-112546198-B | A pharmaceutical composition for treating cerebral apoplexy and acute cerebral infarction | 温州医科大学慈溪生物医药研究院 | 2022-03-25 | — | — | CN | disclosed |
| CN-114133443-A | Fatty acids and their use in conjugation with biomolecules | 诺华股份有限公司 | 2022-03-04 | — | — | CN | disclosed |
| CN-114040771-A | Oral formulations of bioactive peptides and uses thereof | 阿维夫公司 | 2022-02-11 | — | — | CN | disclosed |
| WO-2022025827-A1 | METHOD OF STIMULATING PROLIFERATION OF A CELL | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2022-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260041732-A1 | USE OF APELIN FOR THE TREATMENT OF LYMPHEDEMA | VEGFA, FLT1, APLNR | NMBR 2610/4885GRPR 3069/4885C5AR1 747/4885 |
| US-20260049331-A1 | Sense-and-Response of Proteins, Peptides, and Small Molecules Using Ligand-Induced Dimerization Activating RNA Editing (LIDAR) | ADAR, ZFR, SLIRP | NMBR 1408/4885GRPR 641/4885C5AR1 2358/4885 |
| US-20260097051-A1 | CANNABICHROMENE AS A THERAPEUTIC MODALITY FOR COVID-19 | CNR2, CNR1, IL6 | NMBR 1621/4885GRPR 1497/4885C5AR1 694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.